Valuation: Pelthos Therapeutics Inc.

Market Cap 93.81M 81.98M 75.65M 69.73M 131M 9.03B 134M 904M 356M 4.42B 352M 345M 15.23B P/E 2026 *
-2.31x
P/E 2027 * -14.9x
Enterprise Value 93.81M 81.98M 75.65M 69.73M 131M 9.03B 134M 904M 356M 4.42B 352M 345M 15.23B EV / Sales 2026 *
1.47x
EV / Sales 2027 * 0.77x
Free-Float
46.22%
Yield 2026 *
-
Yield 2027 * -
1 day+1.05%
1 week+1.66%
Current month-4.49%
1 month-6.93%
3 months+17.27%
6 months+17.04%
Current year-12.94%
1 week 24.92
Extreme 24.925
28.51
1 month 23.51
Extreme 23.51
29.76
Current year 18.19
Extreme 18.19
30.99
1 year 16.5
Extreme 16.5
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Sell

Director

-786 0.0226%
02/07/26 Sell

Director

-558 0.0161%
02/07/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%+1.66%+32.96% - 93.81M
+0.85%-0.80%+52.79%+159.97% 1,051B
+1.23%-1.53%+54.58%+59.41% 609B
+0.04%+2.58%+34.47%+84.84% 450B
+0.78%-0.71%+29.28%+23.25% 330B
+1.41%+0.58%+35.44%+40.53% 284B
-0.27%-1.87%+22.34%+19.92% 263B
-1.76%+2.37%-20.43%-38.01% 223B
-1.42%+0.80%+24.27%+57.85% 198B
-1.48%+3.43%+24.08%+70.06% 167B
Average +0.04%+0.65%+28.98%+53.09% 357.52B
Weighted average by Cap. +0.37%+0.02%+37.51%+78.76%

Financials

2026 *2027 *
Net sales 63.92M 55.86M 51.54M 47.51M 89.55M 6.16B 91.53M 616M 242M 3.01B 240M 235M 10.38B 121M 106M 97.72M 90.07M 170M 11.67B 174M 1.17B 459M 5.72B 455M 445M 19.68B
Net income -41.39M -36.17M -33.37M -30.76M -57.98M -3.99B -59.27M -399M -157M -1.95B -155M -152M -6.72B -6.74M -5.89M -5.43M -5.01M -9.44M -649M -9.65M -64.95M -25.55M -318M -25.31M -24.75M -1.09B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
17/07/26 US$26.99 +1.05% 9,899
16/07/26 US$26.71 -1.80% 17,906
15/07/26 US$27.20 +7.09% 34,291
14/07/26 US$25.40 -3.24% 50,104
13/07/26 US$26.25 -1.13% 42,477
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
26.99USD
Average target price
57.71USD
Spread / Average Target
+113.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock